Selenoprotein P (SelenoP) functions as a plasma transporter of selenium (Se) from liver to other tissues via incorporation into multiple selenocysteine (Sec) residues. Selenocysteine lyase (Scly) is an intracellular enzyme that decomposes Sec into selenide, providing Se for the synthesis of new selenoproteins. Both SelenoP and Scly are mostly produced by the liver. Previous studies demonstrated that male mice lacking SelenoP (SelenoP KO) or Scly (Scly KO) had increased or decreased total hepatic Se, respectively. While SelenoP regulation by Se is wellstudied, Scly regulation by Se has not been reported. We hypothesize that Scly is negatively regulated by Se levels, and that absence of SelenoP jeopardizes Scly-dependent Se recycling. Using in vitro and in vivo models, we unveiled a tissue-specific Se regulation of Scly gene expression. We also determined that SelenoP, a considered source of intracellular Se, affects Scly expression and activity in vitro but not in vivo, as in the absence of SelenoP, Scly levels and activity remain normal. We also showed that absence of SelenoP does not increase levels of transsulfuration pathway enzymes, which would result in available selenocompounds being decomposed by the actions of cystathionine γ-lyase (CGL or CTH) and cystathionine β-synthase (CBS). Instead, it affects levels of thioredoxin reductase 1 (Txnrd1), an enzyme that can reduce selenite to selenide to be used in selenoprotein production. This study evaluates a potential interplay between SelenoP and Scly, providing further insights into the regulation of selenium metabolism.
Introduction
Selenium (Se) is a trace element acquired through the diet. Once it is absorbed by the digestive tract, it is carried mostly to the liver where it is metabolized, used for selenoprotein production, and redistributed to other tissues via the bloodstream. Hence, the liver is a central organ in Se metabolism. Se is used to synthesize the amino acid selenocysteine (Sec), found in the active site of selenoenzymes, but of unknown function in other selenoproteins. Sec is co-translationally incorporated into a peptide chain via highly specific incorporation machinery, requiring certain cis and trans factors to function properly.
Sec lyase (Scly) is an enzyme that specifically recognizes the Sec residue [1] and breaks it down into L-alanine and selenide using pyridoxal 5′-phosphate (PLP) as a cofactor for the reaction [2] . The Sec sources that feed into this reaction are believed to be dietary, byproducts of Se metabolism, or following selenoprotein degradation. Decomposition of Sec releases selenide which re-enters Sec synthesis by binding to a phosphate to generate selenophosphate [3, 4] . Selenophosphate is utilized to synthesize Sec on its cognate tRNA [ 
Ser]Sec
, and incorporated into newly translated selenoproteins. Hence, Scly recycles the Se atom.
Tissue-specific Se distribution and recycling mechanisms that compensate for limited Se availability would be advantageous for viability and optimal health, especially in those tissues where the requirement for Se is high. Given its potential importance as a provider of Se for the selenoprotein biosynthesis pathway [5] , it is surprising that the regulation of the Scly gene by Se is unknown. Interestingly, Se was promptly ruled out as a regulator of Scly activity [6, 7] . In humans, no correlation was found between Se levels and Scly activity in the liver, kidney, heart, adrenal gland and muscle [7] . Nevertheless, Scly activity was undetected in the human brain but was found to be active in the brains of rodents. This discrepancy suggests either methodological differences or specific characteristic of the enzyme in human brain. In rats, diets with different chemical forms of Se (selenite, selenomethionine or selenocystine) did not alter Scly activity in the liver, kidney, testis and muscle, even though those Se diets contained concentrations of Se that ranged from 100-fold lower than the basal torula-yeast diet to borderline toxic (0.02 vs. 2 ppm) [6, 8] .
Despite the above reported Scly activity regulation, Scly mRNA levels could be negatively regulated by Se levels, a possibility that was our starting point for this study. We included two separate tissues, the liver, and the brain, in our analysis. The regulation of Scly by Se levels was addressed by in vivo analysis of Scly mRNA expression and activity in mice and in vitro in representative cell lines of these tissues treated with varying Se concentrations.
It is conceivable that protein degradation is one of the Sec sources for Scly action. The plasma selenoprotein P (SelenoP), that contains several Sec residues is, therefore, a possible candidate source of Sec to Scly. To assess the relationship between SelenoP and Scly, we evaluated the expression and activity of Scly in CRISPR-Cas9 SelenoP-depleted hepatic cells and a mouse model of whole-body Se deficiency, the SelenoP KO mouse. Moreover, we assessed the expression of enzymes from alternative pathways such as the transsulfuration pathway and selenite reduction pathways. These pathways metabolize selenocompounds into either selenide for selenoprotein synthesis or selenosugars for excretion and could be compensating for the disruption of SelenoP as a source of Se and consequently maintaining Se metabolism.
Materials & methods

Materials
All chemicals used were from either Sigma-Aldrich or Fisher Scientific unless otherwise noted.
Animals
SelenoP KO heterozygote mice were a kind gift from Dr. Raymond F. Burk from Vanderbilt University (Nashville, TN). Due to the fertility issues [9] , heterozygote mice are used as breeders to obtain homozygote SelenoP KO for experiments. The development and characterization of SelenoP KO mice were previously described in detail [9] . SelenoP and C57BL/6J wild-type (WT) from The Jackson Laboratory (Bar Harbor, ME) were bred, born and raised in the Vivarium at the JABSOM -University of Hawaii. Animals were weaned at 18-21 days and euthanized at ten weeks old. All experiments were conducted in male mice and following the principles and procedures approved by the Institutional Animal Care and Use Committee of the University of Hawaii (protocol #04-017). After experiments, tissues were harvested including brain, lungs, liver, kidneys, testes, and~5 cm segments of the small intestine. Fecal matter was removed from intestinal tissue samples, and tissues were rinsed in 1× phosphate-buffered saline (PBS) before immediate transfer to liquid nitrogen and subsequent storage at −80°C.
Diets
Mice were placed on standard AIN-76A rodent diet (Research Diets, Inc.) containing adequate (0.25 ppm) Se until assigned for experiments. Special diets formulated for precise Se content (Research Diets, Inc.) have been previously described [10] . Briefly, pellets contained 12% kcal fat, 68% kcal carbohydrate, plus 0.08 ppm of Se in casein (low), or were supplemented with sodium selenite to contain a total of 0.25 ppm (adequate) or 1 ppm (high) of Se. Mice were maintained in specific Se diets for two months. SelenoP KO mice were maintained in standard mouse chow containing 0.25-0.3 ppm Se.
Cell culture
Human hepatocellular carcinoma (HepG2), murine hepatocellular carcinoma (Hepa1-6), and murine hippocampal neuronal (Ht22) immortal cell lines from American Type Culture Collection (ATCC) were maintained in 1× Dulbecco's Modified Eagle's Medium (DMEM; GibcoInvitrogen Life Technologies) with 10% fetal bovine serum (FBS; Gibco -Invitrogen Life Technologies) and 1% penicillin-streptomycin-glutamine (PSG; Gibco -Invitrogen Life Technologies) at 37°C with a 5% CO 2 atmosphere. Each batch of FBS was tested for its Se content by mass spectrometry, and the same lot used throughout the study. The lot for our experiments had~30 nM total Se content. Sodium selenite was added to media, reaching final concentrations required for experiments. Cells were grown to 70-80% confluency and harvested after 48 h of selenite supplementation.
Development of SelenoP
-/-Hepa1-6 cells
Hepa1-6 cells with 70-80% confluency had their media changed 24 h before transfection into antibiotic-free DMEM with 10% FBS. Cells were then transfected with either 5 µg of a mouse SelenoP CRISPR/ Cas9-GFP plasmid or 1 µg of a scrambled (SCR)-GFP CRISPR/Cas9 plasmid (Santa Cruz Biotechnology) using Lipofectamine 2000 (Invitrogen Life Technologies) and following manufacturer's protocol. Upon transfection with the SelenoP CRISPR/Cas9-GFP plasmid, cells were cultivated with 20% FBS and supplemented with 40 nM sodium selenite, bringing the final media selenite concentration to 100 nM. After a 48 h incubation period, transfection was confirmed by fluorescent microscopy in an IX71 reflected fluorescence microscope (Olympus). Cell sorting was performed at the University of Hawaii COBRE Molecular and Cellular Immunology Core using a BD FACSAria apparatus (BD Biosciences). Prior to sorting, cells were trypsinized, centrifuged for 4 min at 200 rpm, and resuspended in a 400 µl of RPMI-1640 (Life Technologies) with no Phenol Red. Live cell discrimination was achieved by the addition of propidium iodide. Single cell sorting and single double discrimination were carried out by the BD FACSAria into 96-well plates containing 200 µl of DMEM with 20% FBS and 1% PSG. Single cells were cultured for three weeks after which successful colonies were transferred to larger plates containing DMEM with 10% FBS and 1% PSG. Cells sorted for the presence of the SelenoP CRISPR/ Cas9-GFP plasmid and those sorted for the presence of the control SCR plasmid were grown to 70-80% confluency on 10 cm cell culture plates. DNA from cells was isolated using the DNeasy Blood & Tissue Kit (Qiagen). PCR was then performed using a HotStarTaq DNA Polymerase (Qiagen) following the recommended protocol. Primers flanked the 3′ TGA-rich region of the SelenoP gene. The PCR product was purified using an E.Z.N.A.® Gel Extraction Kit (Omega Bio-Tek) and sequenced at the Advanced Studies in Genomics, Proteomics and Bioinformatics Core Facility at the University of Hawaii to confirm successful SelenoP deletion.
RNA and quantitative PCR (qPCR) analysis
Cells were collected, and total RNA was extracted using Trizol (Invitrogen Life Technologies) followed by treatment with the RNeasy Clean-Up kit (Qiagen). Frozen tissues were pulverized on liquid nitrogen, and total RNA was also extracted by the Trizol method. One microgram of total RNA was then reverse-transcribed (High Capacity cDNA Reverse Transcription kit, Life Technologies/Applied Biosystems) and 10 ng cDNA used in qPCR with SybrGreen (Invitrogen Life Technologies). qPCR results were calculated using the Δ -Ct method, normalized to 18S rRNA or GAPD mRNA as housekeeping genes. PCR primers were used at 100 nM and are listed in Table 1 .
Western blot and antibodies
Protein was collected in CelLytic (Sigma) with a 1:100 ratio of Protease Inhibitor Cocktail Set III, EDTA-Free (EMD Millipore) for both tissue and cell lines. Tissues were sonicated 30-90 pulses, depending on the tissue, using a Sonic Dismembrator Model 100 (Fisher Scientific). Cell lines were placed on shakers for 15 loaded onto a 4-20% SDS-PAGE gel (BioRad), separated out by electrophoresis, and transferred to IPFL membranes (EMD Millipore). We probed blots using commercial specific antibodies for β-actin (Sigma; cat. #A2228), Scly (Santa Cruz Biotechnology; cat. #sc-136394), CTH (Abnova; cat. #H00001491-M03), CBS (antibodies-online; cat. #ABIN3021958), and Txndr1 (Novus Biologicals; cat. #NBP2-20620), at their recommended dilutions. The mouse Scly antibody was validated using our whole-body Scly KO mouse model [11] , and deemed specific in several tissues tested so far (data not shown). Secondary antibodies were linked to IRDye 800CW or IRDye 680LT (Li-Cor Biosciences) at 1:10,000 dilution, and incubated for 45 min before scanning in an Odyssey Infrared Imager (Li-Cor Biosciences). ImageStudio software (Li-Cor Biosciences) was utilized to analyze and quantify blots.
Selenocysteine lyase activity assay
Total protein was collected in PBS containing 5 mM EDTA with a 1:100 ratio of Protease Inhibitor Cocktail Set III, EDTA-Free (EMD Millipore), and concentration measured using the Bradford assay (BioRad). Protein samples were mixed with a solution containing 360 mM Tricine-NaOH pH 9, 2.5 mM Sec, 150 mM dithiothreitol, and 0.06 mM PLP and incubated at 37°C. 20 min after the mixture was added to the protein samples, 5 mM lead acetate in 0.1 N HCl was added to precipitate lead selenide (PbSe). The turbidity of PbSe was assessed in a SpectraMax M3 multi-mode microplate reader (Molecular Devices) at 400 nm within 30 mins and served as a proxy for Scly activity.
Statistical analysis
Results were plotted and analyzed using Prism software (GraphPad Software Inc.). Student's t-test or one-way analysis of variance (ANOVA; 1WA), were applied according to experimental design. P values are shown in the figure legends or graphs. All results are represented as means ± standard error of the mean (SEM).
Results
Effect of Se treatment on Scly expression in vitro
Human hepatoma HepG2 and murine hippocampal neuronal Ht22 cells were treated with three concentrations of Se, 30 nM, 100 nM or 200 nM. These concentrations in cell lines mimic low, adequate and high Se exposure, respectively. The HepG2 and Ht22 cell lines were selected based on the fact that liver and brain are highly Se-dependent. Treatment with 200 nM Se halved Scly gene expression in HepG2 cells compared to treatments of 30 or 100 nM of Se (Fig. 1A) . In the neuronal Ht22 cell line, Scly gene expression remained unchanged in response to varying concentrations of Se (Fig. 1B) .
Effect of Se treatment on Scly expression in vivo
The effects of three levels of dietary sodium selenite on Scly gene expression were tested in vivo using C57BL/6J mice. Scly mRNA levels and Se levels were inversely correlated in both liver (Fig. 1C) and brain  (Fig. 1D) , tissues that are highly dependent on Se for proper function. As dietary Se increased, Scly mRNA levels decreased. In liver, Scly expression doubled when dietary Se was lowest relative to expression with adequate Se, and decreased~25% when dietary Se levels were highest (Fig. 1C) . In the brain, a sharp decrease occurred in Scly expression when dietary Se was highest, without a significant difference between the low and adequate Se concentrations (Fig. 1D) .
Scly expression in SelenoP
SelenoP is a selenoprotein containing multiple Sec residues. SelenoP knockout (KO) mice were previously described to have lower Se levels in most tissues than WT animals, but increased hepatic Se content, when fed a Se adequate diet containing~0.25 ppm selenide [9, 12, 13] . We considered that SelenoP could be an additional source of Sec for Scly function with its levels positively regulating Scly expression and function. The disruption of this gene in an increased Se levels environment, such as the SelenoP KO mouse hepatocytes, would accordingly lead to a decrease in Scly. To investigate the potential correlation between these two proteins, we disrupted the Sec-rich SelenoP gene in murine hepatoma Hepa1-6 cells via transfection of a specific CRISPRCas9-GFP construct specific for SelenoP -/-. After confirmation of SelenoP deletion, we proceeded to assess whether disruption of this gene would affect Scly expression and activity. We observed a significant decrease in Scly protein expression ( Fig. 2A) and activity ( Fig. 2B) in SelenoP -/-Hepa1-6 cells compared to cells transfected with a scrambled CRISPR construct.
Scly expression in the SelenoP KO mouse model
Our results with the SelenoP -/-Hepa1-6 cells invited the question whether Scly expression would also be altered by absence of SelenoP in vivo. The whole-body SelenoP KO mouse serves as a model for understanding localized Se deficiency and adequacy, as Se levels vary in different tissues as reported by other groups [13, 14] . Previous investigations determined that on a low Se diet, the SelenoP KO mice perished after a few weeks of age; this finding was interpreted as being due to insufficient distribution of selenium to the brain. Alternatively, without SelenoP, there would be a deficit in Sec for Scly to recycle for new selenoprotein synthesis. Upon Se supplementation, tissues varied their selenium levels, with liver and kidneys of SelenoP KO mice having highest concentrations of Se than in the same tissues of WT mice [15] . Therefore, the SelenoP KO mouse provided an interesting organismal model to evaluate the relationship between Scly expression and SelenoP in a tissue-specific manner, as long as the mouse were to be kept on a Se-adequate diet.
We assessed Scly gene expression in several tissues of the SelenoP KO mouse model (liver, kidney, testis, lung, and intestines). Scly mRNA expression did not change in most tissues of the SelenoP KO mouse, except in the liver, where Scly mRNA levels were approximately a third of the levels found in their WT counterparts (Fig. 3A) . Nevertheless, such hepatic discrepancy disappeared when we assessed tissues of the SelenoP KO mouse for Scly protein expression and activity. In liver, kidney, testis, and lung of the SelenoP KO mouse, the disruption of SelenoP did not affect either Scly protein levels (Fig. 3B) or Scly activity (Fig. 3C) .
Effect of SelenoP disruption in pathways of Se metabolism
Our results of the maintenance of Scly expression and activity in vivo suggested that, in the absence of Sec-rich SelenoP, other pathways are possibly maintaining the supply of Sec to Scly for maintenance of selenoprotein synthesis. Pathways involved in Se metabolism such as the transsulfuration pathway and selenite reduction could be activated to maintain a Se supply that would ultimately preserve selenoprotein synthesis. These pathways are responsible for metabolizing additional dietary selenocompounds, including the selenomethionine (SeMet) and selenite [16, 17] . Methionine is decomposed into homocysteine via the methionine cycle, with the intermediate homocysteine entering the transsulfuration pathway to produce cysteine and hydrogen sulfide. The transsulfuration pathway can be activated in the presence of structurally similar selenocompounds [16] . SeMet would, therefore, be metabolized into selenohomocysteine, which then is sequentially decomposed into selenocystathionine and Sec by the actions of enzymes cystathionine β-synthase (CBS) and cystathionine γ-lyase (CTH), respectively. Selenite can be reduced to selenide and Se 0 by the action of thioredoxin reductase 1 (Txnrd1) [17] , an essential selenoprotein resistant to variations in Se levels.
We assessed the expression of CBS, CTH, and Txnrd1 in vitro and in vivo, utilizing the SelenoP -/-Hepa1-6 cells and the SelenoP KO mouse models. In cells, we observed an increase in Txnrd1 levels (Fig. 4A) . Nevertheless, levels of CBS and CTH were unaffected by the disruption of SelenoP in Hepa1-6 cells (Fig. 4A) . In the liver of SelenoP KO mice fed an adequate amount of Se, the transsulfuration pathway enzymes were unchanged, while a surprising decrease in Txnrd1 was observed (Fig. 4B) . Bonferroni's post-hoc analysis was performed and asterisks indicate significance levels between specific groups. * P < 0.05, ** P < 0.01, and *** P < 0.001; n in graphs are per group. 
Discussion
Our report is the first to evaluate in vitro and in vivo the regulation of Scly mRNA expression by Se levels and to evaluate the relationship between Scly and SelenoP, a potential intracellular source of Se. Using cell lines representative of two tissues, liver and brain, as well as mouse tissues, we verified that Scly expression differed in response to Se levels in a cell type-specific manner.
Previous studies examining the Se regulation of Scly showed its activity to be neither dependent on Se levels nor Se chemical form (organic or inorganic) [6] . When the mouse Scly cDNA was first cloned, protein expression was shown to follow activity levels with highest Results are mean ± SEM and P values displayed on graphs were calculated by Student's unpaired t-test with 95% confidence interval, ** P < 0.01, n is displayed in graphs.
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Free Radical Biology and Medicine 127 (2018) [182] [183] [184] [185] [186] [187] [188] [189] expression levels in the liver and kidney. Additionally, the Scly protein was shown to be most abundant in the liver, kidneys, and testes, followed by spleen, brain, and heart [18] . It should be noted that the liver is the organ with the second highest accumulation of Se in the rodent body, surpassed only by the kidneys [6] . This correlation indicated a possible regulatory relationship between the presence of Scly and Se levels in each organ. Interestingly, the brain's supply of Se is low but very stable and highly dependent on specific Se uptake. Se distribution is prioritized to the brain which retains most of the available Se upon Se deficiency [19] [20] [21] . Such behavior suggests that specific mechanisms may be in place in the brain to maintain its Se levels. Curiously, the activity of Scly was not detected in the human brain [7] and was only found in low levels in the mouse brain [22] . If the activity of Scly contributes to the Se pool in the brain despite possible changes in Se levels, the downregulation of Scly mRNA could indicate the participation of Scly in controlling Se availability only when Se is limiting. Under Se deficiency, when there is an increase in Se uptake and storage in the brain, Scly could be actively involved in the maintenance of stable Se levels. Taken together, our results suggest that regulation of Scly expression by Se levels may be one of the mechanisms by which the Se supply is differentially regulated in cell types, also contributing to the selenoprotein hierarchy [8] .
The Scly expression pattern in the SelenoP KO mice raises questions about possible uncoupled roles of these two proteins in selenium biology. The unchanged levels of Scly mRNA in most tissues in the SelenoP KO mice could be explained by the fact that animals were kept on a Se-supplemented diet, to assure their survival, as SelenoP KO mice are compromised in a Se-deficient state [23] . We observed that hepatic Scly mRNA levels were sharply downregulated in SelenoP KO mice when compared with WT controls, even though other tissues with diminished levels of Se in the SelenoP KO mice, such as the testis [13] , did not upregulate Scly mRNA in the same fashion. This result suggests that Se from SelenoP may regulate Scly in a tissue-specific manner. Instead of activating recycling mechanisms to compensate for the lack of SelenoP in most tissues of the body, the liver could be where these two proteins, Scly and SelenoP, are regulated in a coordinated fashion to maintain Se availability for the other organs of the body. However, SelenoP protein levels remained unchanged when Scly is disrupted, despite increases in mRNA levels [24] . These combined results suggest that either translational or post-translational mechanisms may be regulating Scly levels despite its mRNA increases, possibly affecting its protein turnover, to sustain Scly activity, and consequently selenoprotein synthesis. These results also suggest an additional unknown player might be involved in the delivery to Scly of Sec coming from degradation of SelenoP. Although most studies have focused on dietary Se intake, selenoprotein degradation and the subsequent recycling of Sec provides an additional, largely unrecognized source of Se to maintain selenoprotein requirements. The mechanism of selenoprotein degradation is still poorly understood. Selenoprotein Dio2 was shown to be ubiquitinated and targeted for proteasomal degradation [25] while selenoproteins V, K, S, methionine sulfoxide reductase B1 (Msrb1) and selenophosphate synthetase 2 (Sephs2) were demonstrated to have their translation termination coupled to a proteolysis-assisted quality control mechanism dependent on CRL2-ubiquitin ligase [26] . The mechanism of SelenoP degradation is currently unknown. Circulating SelenoP utilizes membrane receptors ApoER2 and megalin to enter cells [27] [28] [29] , and the protein itself must be in its oxidized form for uptake to occur [30] . But the mechanism by which SelenoP delivers Sec to Scly is unclear. SelenoP is endocytosed via a clathrin-dependent mechanism, and goes to the lysosomes, possibly for digestion to release the Sec residues. Se from SelenoP was shown to be taken up by cells and utilized in selenoprotein synthesis to increase glutathione peroxidase activity [31] . If SelenoP provides Se for selenoprotein synthesis via Scly, it could possibly deliver the highly reactive Sec residues directly to Scly or through an intermediate, in order to decompose Sec and utilize it in selenoprotein synthesis. The fact that, in the absence of SelenoP, we did not observe significant changes in either expression or activity of Scly suggests that if this interaction occurs, it is possibly mediated by an additional component that remains to be identified. Scly may also not be present in the same cell compartment as where digestion of SelenoP occurs.
Scly activity could also be coupled with the transsulfuration pathway. Due to increases in available Se in the liver when SelenoP is disrupted, the activation of the transsulfuration pathway or selenite reduction to maintain the Se supply towards selenoprotein production are potential expected responses. Our results showed that Trxnrd1, an enzyme that reduces selenite, is upregulated in vitro, but not in vivo. Moreover, the transsulfuration enzymes assessed here, CBS and CTH, were unchanged both in vitro and in vivo. It should be noted that, prior to experiments, SelenoP -/-Hepa1-6 cells had to be supplemented with selenite to maintain cell viability, which could explain the high Txnrd1 in cells, but not in the mouse liver.
Our results demonstrate a cell-specific regulation of Scly expression by Se in vitro and in vivo, and provide evidence that expression and activity of Scly do not correlate with the presence of SelenoP. Future studies focusing on the specific mechanisms for SelenoP degradation may clarify the role of SelenoP as a source of intracellular Se, providing a novel insights into the roles of these two players in selenium metabolism.
